Stocktoria
SINOVAC BIOTECH LTD SVA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-11-13
SINOVAC BIOTECH LTD financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $386.0M | $361.4M | $470.2M | $1.5B | $19.4B |
| Gross profit | $262.0M | $220.7M | $323.3M | $815.2M | $18.4B |
| R&D expense | $216.2M | $270.7M | $350.2M | $478.7M | $152.7M |
| SG&A expense | $333.0M | $420.9M | $598.2M | $836.1M | $602.1M |
| Operating income | -$490.1M | -$505.5M | -$714.0M | -$509.0M | $17.6B |
| Income tax | -$63.3M | $2.2M | $36.4M | $11.5M | $3.4B |
| Net income | — | — | -$13.5M | $14.5M | $8.1B |
| EPS (diluted) | $-0.83 | $1.27 | $-0.19 | $0.20 | $113.44 |
| Operating cash flow | -$512.2M | -$56.9M | $138.6M | -$798.1M | $15.3B |
| Free cash flow | -$561.1M | -$152.9M | -$17.5M | -$1.1B | $14.7B |
| Cash & equivalents | $488.2M | $335.3M | $1.1B | $3.9B | $11.6B |
| Inventory | $94.3M | $96.9M | $135.6M | $175.3M | $391.1M |
| Total assets | $8.5B | $12.3B | $13.6B | $14.0B | $16.8B |
| Total liabilities | $2.1B | $2.0B | $2.0B | $1.8B | $3.2B |
| Shareholders' equity | $6.4B | $10.3B | $11.6B | $12.2B | $13.6B |
Source: SEC EDGAR filings · CIK 0001084201 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.